Ophthalmologists Near Me in Pennsylvania

Wills Eye Hospital / Thomas Jefferson University Hospital | Plymouth Meeting, PA | Retina, macular degeneration, diabetic eye disease

Allen Ho is Professor of Ophthalmology at Sidney Kimmel Medical College and co-directs the Retina Service at Wills Eye. He treats patients with age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, and other diseases of the back of the eye.

Dr. Ho contributed to the phase III study that established ranibizumab injections as a durable treatment for macular edema following branch retinal vein occlusion, a common cause of sudden vision loss in older adults ¹. He also contributed to a long-term analysis of anti-VEGF therapy for diabetic macular edema, which showed that patients who responded well in the first few months kept most of their vision gains years later ³. For patients with diabetes whose blood sugar has just been brought under tight control, his 2018 review on the paradoxical worsening of diabetic retinopathy that can follow ⁴ is a reference point for how to screen and monitor during that window.

Wills Eye Hospital / Thomas Jefferson University Hospital | Philadelphia, PA | Ocular oncology, uveal melanoma, eye tumors

Carol Shields directs the Ocular Oncology Service at Wills Eye, one of the largest eye-tumor practices in the world. She treats children and adults with choroidal melanoma, retinoblastoma, iris tumors, and cancers that spread from elsewhere in the body to the eye.

Dr. Shields led the foundational study on risk factors for growth and metastasis of small choroidal melanocytic lesions ⁶ — the research clinicians still use when deciding whether a small pigmented spot in the back of the eye should be watched or treated. She also led work on plaque radiotherapy for uveal metastases ⁹, which offered a vision-sparing option for patients who would otherwise face removal of the eye, and on uveal melanoma in children and teenagers ¹⁰, a rare presentation that is easy to misdiagnose. Her research on metastatic tumors to the iris ⁷ remains one of the most cited series on how cancers from the breast and lung show up in the front of the eye.

Wills Eye Hospital / Thomas Jefferson University Hospital | Philadelphia, PA | Retina, diabetic macular edema, vitreoretinal surgery

Julia Haller is the Ophthalmologist-in-Chief and CEO of Wills Eye Hospital and chairs Ophthalmology at Sidney Kimmel Medical College. She treats patients with retinal detachments, macular holes, diabetic retinopathy, and macular edema, including cases where standard injections have stopped working.

Dr. Haller was first author on the randomized controlled trial that established the intravitreal dexamethasone implant as a sustained-release treatment for diabetic macular edema ¹¹. For patients who are tired of monthly anti-VEGF shots or whose edema has not resolved, that implant remains one of the main alternatives. She also contributed to a widely cited study on combined cataract surgery and vitrectomy for eyes with both cataract and vitreoretinal disease ¹³, which is relevant when more than one problem needs to be fixed in a single operation, and to work on single-field fundus photography for diabetic retinopathy screening ¹² that shaped how primary care offices now screen diabetic patients for eye disease.

Wills Eye Hospital / Pennsylvania Hospital | Philadelphia, PA | Glaucoma, optical coherence tomography, advanced imaging

Joel Schuman co-directs the Glaucoma Service at Wills Eye and is Vice Chair for Research Innovation at Sidney Kimmel Medical College. He treats patients with glaucoma of all types, including complex and refractory cases.

Dr. Schuman was part of the original team that developed optical coherence tomography, the non-invasive retinal scan now used at nearly every routine eye exam in the country ¹⁴. His subsequent work extended OCT to imaging macular disease ¹⁵, showed that ultrahigh-resolution OCT could reveal detail that earlier systems could not ¹⁶, and demonstrated the first in vivo retinal imaging in humans ¹⁷. He then led the work that turned OCT into a quantitative glaucoma tool by measuring the retinal nerve fiber layer ¹⁸, which is how eye doctors now track whether glaucoma is getting worse year over year. If your glaucoma has been hard to monitor or the pressure has been difficult to control, this is a practice with decades of experience managing patients like you.

Wills Eye Hospital | Plymouth Meeting, PA | Retina, macular degeneration, vitreoretinal surgery

Allen Chiang is Associate Professor of Ophthalmology at Sidney Kimmel Medical College. He treats patients with wet macular degeneration, retinal detachment, macular holes, and complications of prior retinal surgery.

Dr. Chiang was last author and corresponding author on one of the first real-world outcome studies of faricimab — a newer injectable that targets two separate pathways in wet macular degeneration — in patients who had already been treated with other anti-VEGF drugs ²¹. That study matters for patients who have been getting monthly shots for years and want to know if switching to a longer-interval drug is realistic. He also contributed to evidence on intravitreal ocriplasmin for vitreomacular traction and full-thickness macular holes ²⁰ and to surgical technique research on scleral-fixated versus anterior chamber lens implants at the time of vitrectomy ²², which informs what happens when a patient has no capsular support for a standard cataract lens.

Wills Eye Hospital / Thomas Jefferson University Hospital | Philadelphia, PA | Glaucoma, minimally invasive glaucoma surgery, complex glaucoma

Jonathan Myers is Chief of the Glaucoma Service at Wills Eye and Associate Professor of Ophthalmology at Sidney Kimmel Medical College. He treats patients with open-angle, angle-closure, exfoliation, and secondary glaucomas, and performs both traditional and minimally invasive glaucoma surgery.

Dr. Myers led work linking common variants in the LOXL1 gene to exfoliation glaucoma, the most common identifiable cause of secondary glaucoma ²³. That finding helped explain why exfoliation runs in families and why it is more common in some populations than others. He also led a widely cited analysis from the Advanced Glaucoma Intervention Study showing that pressure fluctuation — not just average pressure — is a risk factor for visual field progression even when eye pressure looks well controlled ²⁶. His research on two trabecular iStents combined with a suprachoroidal stent in refractory glaucoma ²⁷ contributed to the body of evidence behind the newer class of minimally invasive glaucoma surgeries now offered to patients who cannot tolerate drops. He also contributed to work on iatrogenic glaucoma from steroid medications ²⁵ and to the Boston keratoprosthesis series, which treats patients with corneal disease whose transplants have failed ²⁴.